Harlan M. Krumholz, MD, SM
September 1st, 2013
A TASTE of Registry-Based Randomized Trials
Ole Frobert, MD, PhD and Harlan M. Krumholz, MD, SM
Ole Fröbert discusses his study group’s registry-based randomized trial of pre-PCI thrombus aspiration in STEMI patients.
August 26th, 2013
Practice Variations and Quality: Ask the “Uber” Expert
Richard A. Lange, MD, MBA and Harlan M. Krumholz, MD, SM
In light of reported variation in practice and outcomes of elective PCI, Rick Lange asks Harlan Krumholz to elaborate on what constitutes high-quality decision making.
August 26th, 2013
Missing Data And The ATLAS ACS 2-TIMI 51 Trial
Sanjay Kaul, MD and Harlan M. Krumholz, MD, SM
What is the impact of the larger than usual amount of missing data in the ATLAS ACS 2-TIMI 51? A member of the FDA’s Cardiovascular and Renal Drugs Advisory panel answers questions about this issue.
August 20th, 2013
A Pathway to Preventing Research Fraud
Harlan M. Krumholz, MD, SM
Is the road to fraud-free research paved with publicly accessible raw data?
August 5th, 2013
Putting the 2013 Heart Failure Guidelines Into Practice
Clyde Yancy, MD, Harlan M. Krumholz, MD, SM and John Ryan, MD
CardioExchange’s Harlan Krumholz and John Ryan interview Clyde W. Yancy, lead member of the ACCF/AHA task force that wrote the 2013 guidelines for management of heart failure. Krumholz and Ryan: What is the biggest challenge to implementing the heart failure guidelines for every patient with heart failure? Yancy: The biggest challenge is no longer in establishing “proof.” […]
July 16th, 2013
What You Need To Know About Statins
Huseyin Naci, MHS, PhD Candidate, Jasper Brugts, Md phd msc and Harlan M. Krumholz, MD, SM
The authors of the largest meta-analysis to date on the side effects of statins discuss their findings and weigh the risks and benefits of statins for primary prevention.
June 17th, 2013
Douglas Zipes: Portrait of the Electrophysiologist as a Novelist
Douglas P Zipes, MD, John Ryan, MD and Harlan M. Krumholz, MD, SM
Renowned electrophysiologist Douglas Zipes discusses his second career as a writer of thrillers.
April 9th, 2013
The TACT Investigators Respond to Questions
Gervasio Antonio Lamas, MD, Daniel Mark, Christine Goertz, DC, PhD, Robin Boineau, M.D., M.A., Kerry L. Lee, Ph.D. and Harlan M. Krumholz, MD, SM
The publication in JAMA of the NIH’s Trial to Assess Chelation Therapy (TACT) has reignited a heated debate about the trial. The TACT investigators have generously agreed to respond to questions posed by Harlan Krumholz.
March 21st, 2013
DIGging In: Three Reasons Why the Recent Digoxin Study Is Not Relevant to Readmission
Harlan M. Krumholz, MD, SM
The evidence is just not compelling that this this drug would reduce hospital readmissions
February 12th, 2013
Conflict Of Interest Is A Complex Issue
Robert McKinnon Califf, MD and Harlan M. Krumholz, MD, SM
In a recent editorial in the Journal of the American College of Cardiology, Robert Califf discusses a few of the many complex questions related to the conflict of interest issue. Here CardioExchange’s Harlan Krumholz further explores the issue with Califf. CardioExchange: Do you think that conflict of interest issues are mostly an issue about optics and not […]
NEJM Journal Watch — Recent Cardiology Articles- To Lower Stroke Risk in Patients Undergoing Atrial Fibrillation Ablation, Is a Device or a Medication Better?
- Intensive vs. Standard Blood Pressure Lowering in Patients with Diabetes
- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy